A number of genetic and epigenetic alterations have been identified in glioblastoma that lead to the dysregulation of signaling pathways, including activation of the receptor tyrosine kinase pathway, PTEN–PI3K–Akt activation, and inhibition of p53 [28]. The gene discussed is NTRK1; the disease is glioblastoma.